TSNDF
TerrAscend Corp.
OTC Markets OTCQXUSDEQUITY
Healthcare
DELAYED
Last price
0.63
▲ 0.02 (3.61%)
MARKET · —
Price
Open
0.62
Prev close
0.61
Day high
0.65
Day low
0.61
Volume
123.42K
Market cap
$235.53M
P/E (TTM)
—
52W range
0.35 – 1.45
Trailing performance
Returnvs SPY
1W
+8.22%
+9.6%
1M
+20.15%
+16.4%
3M
-3.51%
-6.6%
6M
+10.10%
-1.0%
YTD
-12.22%
-24.5%
1Y
-36.10%
-56.1%
3Y
-62.16%
-136.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$235.53M
Enterprise value$401.23M
Revenue (TTM)$263.91M
Gross profit$139.26M
EBITDA$60.83M
Net income$-31.79M
EPS (TTM)$-0.10
Free cash flow$20.94M
Total cash$42.12M
Total debt$243.61M
Book value / share$0.29
Shares outstanding309.18M
Float220.67M
Short % of float—
Dividend yield—
Beta (5Y)2.02
Valuation & profitability ratios
Trailing P/E—
Forward P/E126.40
PEG ratio—
Price / sales—
Price / book2.22
EV / revenue1.52
EV / EBITDA6.60
Gross margin52.77%
Operating margin18.05%
Profit margin-15.72%
Return on equity-26.98%
Return on assets4.99%
Debt / equity289.87
Current ratio1.83
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $260.08M | $306.68M | $317.33M | $247.83M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$86.23M | -$80.23M | -$95.55M | -$329.91M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$86.23M | -$80.23M | -$95.55M | -$329.91M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.01 | -0.03 | -194.0% |
| Mar 2026 | -0.02 | -0.03 | -88.7% |
| Dec 2025 | -0.01 | 0.01 | +225.5% |
| Sep 2025 | -0.02 | -0.03 | -59.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.02 | 2 | $66.80M | +2.6% |
| Next quarter | 0.03 | 2 | $67.50M | +2.8% |
| Current year | -0.04 | 2 | $266.97M | +2.7% |
| Next year | 0.01 | 2 | $285.73M | +7.0% |
Analyst targets & ownership
Mean target$1.50
High target$1.50
Low target$1.50
Implied upside137.34%
Analyst count1
ConsensusNONE
Strong buy / Buy1 / 2
Hold0
Sell / Strong sell0 / 0
Held by insiders5.46%
Held by institutions14.01%
Institutions holding7
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
16.88M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Apr 8, 26 | Gefen (Lynn Katzler) Senior Officer of Issuer |
— | 10.18K | — | Direct |
| Apr 8, 26 | Ghanem (Ziad) Senior Officer of Issuer |
— | 40.80K | — | Direct |
| Apr 7, 26 | Gefen (Lynn Katzler) Senior Officer of Issuer |
— | 7.67K | — | Direct |
| Apr 7, 26 | Ghanem (Ziad) Senior Officer of Issuer |
— | 18.52K | — | Direct |
| Apr 4, 26 | Gefen (Lynn Katzler) Senior Officer of Issuer |
— | 69.86K | — | Direct |
| Apr 4, 26 | Ghanem (Ziad) Senior Officer of Issuer |
— | 194.66K | — | Direct |
| Mar 23, 26 | Ghanem (Ziad) Senior Officer of Issuer |
— | 4.47K | — | Direct |
| Dec 31, 25 | Collard (Craig Alexander) Director of Issuer |
— | 433.65K | — | Direct |
| Dec 31, 25 | Dioguardi (Kara Denise) Director of Issuer |
— | 407.69K | — | Direct |
| Dec 31, 25 | Duarte (Ira) Director of Issuer |
— | 433.65K | — | Direct |
| Dec 31, 25 | Schutter (Edward James) Director of Issuer |
— | 422.12K | — | Direct |
| Dec 31, 25 | Wild (Jason) 10% Security Holder of Issuer |
— | 1.36M | — | Direct |
| Nov 24, 25 | Schutter (Edward James) Director of Issuer |
SELL | 46.17K | $19.95K | Direct |
| Nov 24, 25 | Schutter (Edward James) Director of Issuer |
SELL | 11.30K | $4.92K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Collard (Craig Alexander) |
Director of Issuer | 1.07M | Exercise of rights |
Dioguardi (Kara Denise) |
Director of Issuer | 680.06K | Exercise of rights |
Duarte (Ira) |
Director of Issuer | 657.93K | Exercise of rights |
Gefen (Lynn Katzler) |
Senior Officer of Issuer | 130.80K | Exercise of rights |
Ghanem (Ziad) |
Senior Officer of Issuer | 423.54K | Exercise of rights |
Schutter (Edward James) |
Director of Issuer | 1.87M | Exercise of rights |
Wild (Jason) |
10% Security Holder of Issuer | 10.92M | Exercise of rights |
Moving averages & technicals
SMA 10
0.58
+8.52% from price
SMA 20
0.55
+15.88% from price
SMA 50
0.59
+7.74% from price
SMA 100
0.64
-0.95% from price
SMA 200
0.65
-2.99% from price
EMA 12
0.58
+9.09% from price
EMA 26
0.57
+10.90% from price
EMA 50
0.59
+7.70% from price
RSI (14)
61.1
Neutral
MACD (12,26,9)
0.01
Hist 0.01
ATR (14)
0.06
9.60% of price
Realised vol 30D
86.6%
Annualised
Bollinger upper
0.64
20, 2σ
Bollinger lower
0.45
20, 2σ
50 / 200 cross
Death
0.59 vs 0.65
Trend bias
Below 200
-2.99%
Risk profile
Beta vs SPY
1.39
More volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
86.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-67.0%
Peak to trough
Max drawdown 5Y
-96.8%
Peak to trough
ATR 14
0.06
9.60% of price
Beta (reported)
2.02
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
TerrAscend to Renew $10 Million Share Repurchase Program
MT Newswires · 2d ago
TerrAscend Announces Renewal and Replenishment of $10 Million Share Repurchase Program
GlobeNewswire · 2d ago
TerrAscend Reports Wider Loss, Higher Revenue for Second Quarter
MT Newswires · 16d ago
TerrAscend Reports Second Quarter 2026 Financial Results
GlobeNewswire · 16d ago
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
Zacks · 18d ago
TerrAscend to Host Second Quarter 2026 Earnings Conference Call
GlobeNewswire · 37d ago
TerrAscend to Buy 5th Dispensary in New Jersey For $9 Million
MT Newswires · 53d ago
TerrAscend Signs Agreement to Acquire Fifth Dispensary in New Jersey
GlobeNewswire · 53d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.